Revolution Medicines Presents Overall Survival Data for RASONQUE™ (daraxonrasib) Across Subgroups in Previously Treated Metastatic Pancreatic Cancer at ESMO 2026
Revolution Medicines presented exploratory subgroup analyses from the Phase 3 RASolute 302 trial at ESMO 2026 as a late-breaking abstract (LBA82), showing RASONQUE (daraxonrasib) delivered a consistent overall survival benefit versus chemotherapy across all evaluated RAS genotype subgroups in previously treated metastatic pancreatic cancer. The previously reported primary analysis showed median overall survival of 13.2 months with RASONQUE versus 6.7 months with chemotherapy (HR 0.40). Subgroup hazard ratios ranged from 0.32 (G12V) to 0.61 (G12R), and the benefit held even in tumors with no identified RAS mutation (HR 0.43) and across all standard chemotherapy regimens.
Key figures
- Drug Name
- RASONQUE (daraxonrasib)
- Phase Of Trial
- Phase 3
- Os hr q61
- 0.37
- Os hr g12d
- 0.49
- Os hr g12r
- 0.61
- Os hr g12v
- 0.32
- Chemo arm n
- 252
- Data cutoff
- February 10, 2026
- Rasonque arm n
- 248
- Os hr no ras mutation
- 0.43
- Median followup months
- 8.5
- Median os chemo months
- 6.7
- Overall os hazard ratio
- 0.4
- Median os rasonque months
- 13.2
AI analysis
The rest of the AI analysis, red flags and sentiment are part of Signal8 Pro.
AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.